Harvest Fund Management Co., LTD Exelixis, Inc. Transaction History

Harvest Fund Management Co., LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$19.25 - $24.13 $10,895 - $13,657	-566 Reduced 74.08%	198 $4,000
Q3 2023 Nov 06, 2023	BUY	$19.04 - $22.74 $12,147 - $14,508	638 Added 506.35%	764 $17,000
Q2 2023 Jul 07, 2023	SELL	$18.17 - $20.48 $58,271 - $65,679	-3,207 Reduced 96.22%	126 $2,000
Q1 2023 May 10, 2023	BUY	$16.3 - $19.41 $54,327 - $64,693	3,333 New	3,333 $65,000
Q4 2020 Feb 10, 2021	SELL	$18.39 - $24.8 $29,589 - $39,903	-1,609 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$20.67 - $26.94 $33,258 - $43,346	1,609 New	1,609 $38,000
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $30,969 - $40,491	-1,636 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$19.6 - $24.76 $32,065 - $40,507	1,636 New	1,636 $39,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Harvest Fund Management Co., LTD, based on Form 13F filings with the SEC.

Stay updated on Harvest Fund Management Co., LTD with notifications on news.